Seer to Apply Deep Proteomics Tech to Singapore Population Cohort Study

Why It Matters

The partnership delivers deep, unbiased proteomics at population scale, accelerating biomarker identification and precision‑medicine insights for under‑represented Asian cohorts, a critical step for global drug development and health risk modeling.

Key Takeaways

• Seer’s Proteograph will profile plasma proteome of 10,000 Singapore participants.
• Study combines Seer data with Thermo Fisher’s Olink Reveal and Orbitrap Astral.
• PRECISE‑SG100K aims to create a 100,000‑person multi‑omic Asian dataset.
• Multi‑omic data will accelerate biomarker discovery for cardiometabolic, eye, neurologic diseases.
• Partnership showcases integrated deep proteomics solution for population‑scale research.

Pulse Analysis

Deep proteomics is moving beyond the laboratory and into large‑scale population studies, and Seer’s Proteograph® is at the forefront of this shift. By delivering high‑throughput, unbiased plasma protein profiling, the platform complements next‑generation sequencing‑based assays like Thermo Fisher’s Olink Reveal and the high‑resolution Orbitrap Astral mass spectrometers. This technological synergy enables researchers to capture a broader swath of the proteome, providing richer data layers that can be directly linked to genetic variation and clinical phenotypes, a capability that was previously limited to smaller cohorts.

The PRECISE‑SG100K initiative represents a landmark effort to map health and disease across a multi‑ancestry Asian population. Enrolling roughly 100,000 residents, the study integrates genomics, proteomics, lifestyle surveys, imaging, and other health metrics, creating a holistic view of disease risk factors. The inclusion of Seer’s deep proteomics data for 10,000 participants enhances the resolution of protein networks, allowing scientists to pinpoint how genetic and environmental factors converge on disease pathways. This comprehensive dataset is poised to become a reference resource for researchers worldwide, addressing the historic under‑representation of Asian genomes in biomedical research.

The implications for industry are significant. A richer multi‑omic repository accelerates biomarker discovery in cardiometabolic, ophthalmic, and neurologic disorders, informing drug target validation and patient stratification strategies. Predictive models built on this data can improve risk assessment and therapeutic response predictions, supporting the rise of precision medicine tailored to diverse populations. Moreover, the successful integration of Seer’s and Thermo Fisher’s platforms showcases a scalable model for future population‑scale studies, likely spurring additional collaborations and investment in high‑dimensional omics technologies.